NCT06600022View on ClinicalTrials.gov

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

441

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions

Advanced Malignant Solid Tumours

Interventions

DRUG

SCTB41

SCTB41 of different doses,IV,every 3 weeks

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sinocelltech Ltd.

INDUSTRY